Humana's announcement indicates that the 2025 Stars results will not affect its financial outlook for the next two years, suggesting stability in the short term. However, the mention of increased risks in achieving a 3% margin target by 2027 introduces some uncertainty. The company's initiatives to improve performance could be seen as a positive long-term strategy, but the immediate impact on stock price is likely neutral.